Acetyl-L-carnitine

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: energy focus memory

Research Overview

Across the provided abstracts, acetyl‑L‑carnitine (ALC) and related L‑carnitine interventions have been studied most often in cardiometabolic contexts—particularly metabolic syndrome, insulin resistance, type 2 diabetes, and associated risk factors such as hypertension, dyslipidemia, central adiposity, and inflammatory/adipokine markers. The evidence base includes small pilot trials (including infusion studies and oral supplementation), adjunctive-therapy trials in diabetes (e.g., with glimepiride, simvastatin, or orlistat), and a systematic review/meta-analysis of randomized controlled trials evaluating metabolic syndrome biomarkers over 8–24 weeks at ~0.75–3 g/day. Some studies also examine symptom outcomes during metabolic stress (e.g., fasting-induced hunger and fatigue) and liver-related enzymes during fasting.

The strongest evidence in these abstracts supports modest improvements in selected cardiometabolic endpoints, with the most consistent signals for reductions in waist circumference and systolic blood pressure (meta-analysis), and improvements in insulin sensitivity in insulin-resistant individuals (ALC 1 g twice daily for 24 weeks increased glucose disposal rate in those with low baseline insulin sensitivity). Adjunctive trials in type 2 diabetes and dyslipidemia generally report additional improvements versus standard therapy alone in glycemic control (fasting/postprandial glucose, HbA1c), insulin resistance indices (e.g., HOMA-IR), triglycerides, and some lipoprotein measures (including reported reductions in Lp(a)/apo(a) in one simvastatin coadministration trial). A short, single-blind pilot study using intravenous L-carnitine during a fasting intervention suggests potential benefits on fasting tolerability (hunger, fatigue) and some metabolic/liver markers, but its design and small sample size limit inference.

Key gaps remain. Many studies are small, heterogeneous (ALC vs L-carnitine; oral vs intravenous; varying doses and durations), and often evaluate intermediate biomarkers rather than hard clinical outcomes. More research is needed to clarify dose–response relationships, identify which subgroups benefit most (e.g., those with demonstrable insulin resistance), and determine durability after discontinuation (some outcomes appeared to regress post-treatment). Larger, well-controlled, longer-term RCTs should test whether observed improvements in insulin sensitivity, blood pressure, and lipid parameters translate into reduced incidence of diabetes complications and cardiovascular events, while also standardizing outcome measures and systematically assessing safety and tolerability across populations and concomitant therapies.

1. What conditions has Acetyl-L-carnitine been studied for?

  • Insulin resistance and impaired glucose tolerance in people at increased cardiovascular risk (24-week oral acetyl-L-carnitine; insulin sensitivity measured by hyperinsulinemic-euglycemic clamp).

  • Arterial hypertension (high blood pressure) in the same cardiovascular-risk cohort (blood pressure tracked during and after acetyl-L-carnitine treatment).

  • Metabolic syndrome (MetS) biomarkers (systematic review/meta-analysis of RCTs of oral L-carnitine; outcomes included waist circumference, blood pressure, fasting blood sugar, triglycerides, HDL-C).

  • Type 2 diabetes (T2DM) for glycemic control, insulin resistance markers, lipids, and oxidative stress (multiple RCTs of oral L-carnitine; and add-on studies with glimepiride; and with simvastatin).

  • Obesity with uncontrolled T2DM as an adjunct to weight-loss drugs (orlistat + L-carnitine; sibutramine + L-carnitine) assessing weight, glycemia, lipids, and inflammatory markers over 12 months.

  • Fasting-related adverse effects during a modified fasting program in metabolic syndrome patients (7-day pilot RCT using intravenous L-carnitine; outcomes included hunger, fatigue, liver enzymes, lipids, weight loss).

  • Oxidative stress / oxidized LDL in T2DM (3-month RCT measuring oxidized LDL and lipid peroxidation markers).

Note: Most abstracts are on L-carnitine; one key study is specifically acetyl-L-carnitine. Findings may not be fully interchangeable across forms and routes (oral vs IV).

2. Does it work in treating those conditions? Summarize the evidence.

  • Insulin resistance (acetyl-L-carnitine): In a 24-week oral acetyl-L-carnitine study (1 g twice daily), insulin sensitivity improved in participants with lower baseline glucose disposal rate (GDR ≤ 7.9 mg/kg/min): GDR increased from 4.89 ± 1.47 to 6.72 ± 3.12 (P = 0.003). No benefit was seen in those with higher baseline GDR, suggesting effect modification by baseline insulin resistance severity.

  • Blood pressure (acetyl-L-carnitine): In the same 24-week study, systolic BP decreased in both baseline GDR strata (overall P < 0.001), and then partly returned toward baseline after stopping (8-week post-treatment observation), suggesting the BP effect may require ongoing use.

  • Metabolic syndrome biomarkers (mostly L-carnitine): A systematic review/meta-analysis of RCTs (0.75–3 g/day for 8–24 weeks) found significant reductions in waist circumference and systolic BP, with no overall significant effects on fasting blood sugar, triglycerides, or HDL-C. However, subgroup findings suggested doses >1 g/day were associated with improved fasting blood sugar and triglycerides and increased HDL-C (dose-response signal, but dependent on subgroup analysis).

  • Type 2 diabetes glycemia and insulin resistance (L-carnitine): Evidence is mixed but includes several positive trials:

    • Add-on to glimepiride for 6 months (1 g twice daily) improved FBG, PPBG, HbA1c, fasting insulin, and HOMA-IR versus glimepiride alone; also improved inflammatory/adipokine markers (TNF-α, visfatin) and lipid panel, but no effect on BMI or BP in that study.

    • In a 12-week RCT (1 g three times daily), fasting plasma glucose decreased (143 ± 35 to 130 ± 33 mg/dL; P = 0.03), but triglycerides increased (P = 0.05) and ApoA1/ApoB100 increased—showing potentially conflicting lipid effects across studies.

  • Lipids and oxidative stress in T2DM (L-carnitine): A 3-month RCT (2 g/day) reported reductions versus placebo in oxidized LDL (decrease 15.1 vs 3.0 U/L; P < 0.001), LDL-C (P < 0.05), triglycerides (P < 0.001), and lipid peroxidation markers (TBARS, conjugated dienes; P < 0.001).

  • Adjunct to weight-loss drugs in obese/uncontrolled T2DM (L-carnitine): Two 12-month trials reported that adding L-carnitine (2 g/day) to orlistat or sibutramine produced greater and/or faster improvements in weight, glycemic control, insulin resistance (HOMA-IR), lipids, and inflammatory markers than the drug alone. Interpretation is limited because these are combination-therapy designs (incremental benefit is plausible, but attribution solely to carnitine is less certain than in placebo-controlled monotherapy trials).

  • Fasting tolerance and weight loss during fasting (IV L-carnitine): In a 7-day pilot RCT in MetS patients undergoing modified fasting, IV L-carnitine (4 g/day) improved hunger and fatigue scores versus saline and was associated with greater weight loss and waist reduction. This is short-term, small (n=30), and uses IV dosing during a specific fasting protocol, limiting generalizability to typical oral supplementation.

Overall, the abstracts suggest potential benefits for insulin resistance and some cardiometabolic markers, but results vary by population, baseline metabolic status, dose, duration, and whether carnitine is used alone or as add-on therapy.

3. What health benefits does it have?

  • Improved insulin sensitivity in insulin-resistant individuals (acetyl-L-carnitine 1 g twice daily for 24 weeks increased clamp-measured GDR in those with low baseline GDR).

  • Lower blood pressure (acetyl-L-carnitine reduced systolic BP during treatment; meta-analysis of L-carnitine RCTs also found reduced systolic BP; IV L-carnitine during fasting prevented BP increases seen in controls).

  • Reduced central adiposity markers (meta-analysis: reduced waist circumference; fasting pilot: larger waist reduction with IV L-carnitine; combination trials reported better weight outcomes when added to anti-obesity drugs).

  • Glycemic improvements in T2DM (some studies) including reductions in fasting glucose and HbA1c in add-on settings (e.g., with glimepiride; and improved glycemia in combination with simvastatin in one trial).

  • Improved oxidative stress markers in T2DM (2 g/day reduced oxidized LDL and lipid peroxidation markers vs placebo over 3 months).

  • Potential improvements in inflammatory/adipokine profiles in T2DM combination/add-on studies (reported improvements in TNF-α, adiponectin, leptin, vaspin, hs-CRP in orlistat/sibutramine add-on trials; adiponectin changes also tracked with acetyl-L-carnitine in the cardiovascular-risk study).

  • Improved fasting tolerability (IV L-carnitine reduced perceived hunger and fatigue during a fasting intervention in MetS patients).

4. Does it have any downsides or side effects?

  • Mixed or adverse lipid changes in at least one RCT: In a 12-week trial in T2DM (1 g three times daily), fasting triglycerides increased (196 ± 61 to 233 ± 12 mg/dL; P = 0.05) and ApoB100 increased (P = 0.02), despite improved fasting glucose. This suggests lipid responses may be variable and could worsen in some contexts.

  • Limited adverse-event reporting in these abstracts: The acetyl-L-carnitine 24-week study states treatment was “well tolerated,” and the sibutramine + L-carnitine trial reports no severe adverse effects, but the abstracts do not provide detailed side-effect rates (e.g., GI symptoms, insomnia, etc.).

  • Route/dose considerations: One study used IV L-carnitine 4 g/day during fasting; safety and tolerability of IV protocols may not translate to typical oral acetyl-L-carnitine supplements.

  • Durability of effect: In the acetyl-L-carnitine study, systolic BP “progressively recovered toward baseline” after stopping over 8 weeks, implying benefits may not persist without continued use.

Because these are abstracts, they may omit less common adverse effects and do not address broader safety topics sometimes discussed for carnitine (e.g., long-term outcomes). Based strictly on the provided abstracts, the clearest “downside signal” is the triglyceride increase observed in one diabetic RCT.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic analyses (no genotype-stratified outcomes, no variant-specific dosing, and no responder/non-responder genetics). Therefore, based on these abstracts alone:

  • No specific genetic variants can be identified as predicting benefit or harm from acetyl-L-carnitine/L-carnitine.

  • The closest evidence of “differential response” is phenotypic rather than genetic: acetyl-L-carnitine improved insulin sensitivity primarily in those with lower baseline GDR (more insulin resistant), suggesting baseline metabolic status may be a stronger predictor of response than any genetic factor described here.

References

  1. L-carnitine ameliorated fasting-induced fatigue, hunger, and metabolic abnormalities in patients with metabolic syndrome: a randomized controlled study
    Jun-jie Zhang, Zhi-bing Wu, You-jin Cai, Bin Ke, Ying-juan Huang (2014)
  2. L-Carnitine's Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Munji Choi, Seongmin Park, Myoungsook Lee (2020)
  3. Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy
    Piero Ruggenenti, Dario Cattaneo, Giacomina Loriga, Franca Ledda, Nicola Motterlini (2009)
  4. Comparative study to evaluate the effect of l-carnitine plus glimepiride versus glimepiride alone on insulin resistance in type 2 diabetic patients
    Hadier M El-Sheikh, Sahar M El-Haggar, Tamer A Elbedewy (2019)
  5. Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus
    Fabio Galvano, Giovanni Li Volti, Michele Malaguarnera, Teresio Avitabile, Tijana Antic (2009)
  6. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients
    Giuseppe Derosa, Pamela Maffioli, Ilaria Ferrari, Angela D'Angelo, Elena Fogari (2011)
  7. Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients
    Giuseppe Derosa, Pamela Maffioli, Sibilla A T Salvadeo, Ilaria Ferrari, Alessia Gravina (2011)
  8. L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes
    Mariano Malaguarnera, Marco Vacante, Teresio Avitabile, Marcella Malaguarnera, Lisa Cammalleri (2009)
  9. Effect of L-carnitine on plasma glycemic and lipidemic profile in patients with type II diabetes mellitus
    A R Rahbar, R Shakerhosseini, N Saadat, F Taleban, A Pordal (2005)
  10. Effect of carnitine-orotate complex on glucose metabolism and fatty liver: a double-blind, placebo-controlled study
    Eun Shil Hong, Eun Ky Kim, Seon Mee Kang, Ah Reum Khang, Sung Hee Choi (2014)
  11. Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus
    Vincenzo Solfrizzi, Cristiano Capurso, Anna M Colacicco, Alessia D'Introno, Cristina Fontana (2006)
  12. Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial
    Aneliya Parvanova, Matias Trillini, Manuel A Podestà, Ilian P Iliev, Carolina Aparicio (2018)
  13. The effects of oral L-carnitine treatment on blood lipid metabolism and the body fat content in the diabetic patient
    Y Liang, Y Li, J Shan, B Yu, Z Ho (1998)
  14. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus
    Giuseppe Derosa, Arrigo F G Cicero, Antonio Gaddi, Amedeo Mugellini, Leonardina Ciccarelli (2003)
  15. The effects of L-carnitine supplementation on cardiovascular risk factors in participants with impaired glucose tolerance and diabetes: a systematic review and dose-response meta-analysis
    Rezvan Gheysari, Mahlagha Nikbaf-Shandiz, Amir Mehdi Hosseini, Niloufar Rasaei, Shabnam Hosseini (2024)
  16. Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial
    Sheyu Li, Xiang Chen, Qianrui Li, Juan Du, Zhimin Liu (2016)
  17. Effect of oral L-carnitine administration on insulin sensitivity and lipid profile in type 2 diabetes mellitus patients
    Manuel González-Ortiz, Sandra O Hernández-González, Eduardo Hernández-Salazar, Esperanza Martínez-Abundis (2008)
  18. The effects of L-carnitine supplementation on glycemic markers in adults: A systematic review and dose-response meta-analysis
    Mohammad Zamani, Naseh Pahlavani, Mahlagha Nikbaf-Shandiz, Niloufar Rasaei, Rasool Ghaffarian-Ensaf (2023)
  19. L-carnitine improves glucose disposal in type 2 diabetic patients
    G Mingrone, A V Greco, E Capristo, G Benedetti, A Giancaterini (1999)
  20. Caloric restriction and L-carnitine administration improves insulin sensitivity in patients with impaired glucose metabolism
    Alessio Molfino, Antonia Cascino, Caterina Conte, Cesarina Ramaccini, Filippo Rossi Fanelli (2010)


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!